376 results about "Integrin" patented technology

Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a cascade response type nano-particle with a microenvironment remodeling function and a preparation method and application of the cascade response type nano-particle. The nanoparticle provided by the invention adopts a bionic hybrid membrane engineering strategy: an inner core is formed by loading an exosome inhibitor on a nano material, and the surface is covalently coupled with M2 type macrophage specific targeting peptide; the outer layer coats a macrophage membrane and active oxygen response type liposome composite membrane layer through a co-extrusion technology, and is loaded with a TLR agonist. Animal experiments show that after being injected through caudal vein, the nano-particles are enriched at a tumor site in a targeted manner through homing receptors such as membrane surface integrin alpha4beta1 and the like, and outer membrane cracking is triggered in a high-ROS tumor microenvironment, so that space-time controlled release of a TLR agonist and targeted phagocytosis of an exosome inhibitor by macrophages guided by a targeted peptide are realized. The anti-tumor synergistic effect is achieved through multiple regulation and control mechanisms, and an effective treatment strategy is provided for tumor immunotherapy.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant human III-type collagen for promoting angiogenesis as well as a preparation method and application of the recombinant human III-type collagen. The recombinant human III-type collagen for promoting angiogenesis has an amino acid sequence as shown in SEQ ID NO. 1. Nine different sites of the full-length natural III-type collagen are replaced by GFOGER sequences which are from the I-type collagen and are specifically combined with integrin sites, the angiogenesis promoting function of the collagen is enhanced under the condition that the total length of natural full-length amino acid is not changed, and meanwhile, four natural integrin sites with low adhesion rate are also replaced; the recombinant III-type collagen has high adhesive force, so that angiogenesis is further promoted. By means of the transformation mode, the angiogenesis rate is increased by 37% or above, the molecular weight of the translated protein is moderate, and the translated protein is easy to prepare.

The present invention provides: a drug which can improve the implantation rate of an embryo and can be used in conjunction with conventional drugs for infertility treatment; and a screening method and the like with which it is possible to reliably evaluate such a drug. Specifically, the integrin activator comprises: (1) a peptide composed of KFEERMRCKWMT, and (2) a peptide composed of KFEERMRCKWMT. (2) a peptide which is composed of KFEEERSRCKWMT; (3) a peptide comprising an amino acid sequence obtained by deleting, substituting and / or adding 1-3 amino acids in (1) or (2); or (4) a peptide obtained by binding any one of (1) to (3) to a membrane-permeable molecule. Provided are an artificial uterus and a screening method based on an implantation reproduction test system using a fertilized egg (for example, an embryo developed to an implanted blastocyst), the artificial uterus comprising: a hydrogel containing endometrial stromal cells and having an extracellular matrix as a main component; and a uterine epithelial organoid configured to be surrounded by the hydrogel.

The invention provides a fusion protein for promoting proliferation of hair follicle stem cells as well as a preparation method and application of the fusion protein. The fusion protein is formed by fusion expression of a plurality of collagen structural domains capable of being combined with cell integrin and / or specific structural domains from certain functional proteins screened from collagen XVII and III type collagen. Nucleic acid molecules for coding the fusion protein are subjected to codon optimization and then recombined and stably expressed in escherichia coli to obtain the fusion protein. The fusion protein has excellent performance of promoting proliferation and migration of human hair follicle stem cells and human fibroblasts, can be used for repairing skin and hair follicle tissues and improving resistance of skin and hair follicles, and is suitable for popularization and application in the fields of beauty and skin care, medical equipment, tissue engineering and the like.

Provided is a compound for double targeting of a fibroblast activation protein and an integrin subtype, comprising: (i) a chelating ligand moiety (CL); (ii) a first targeting moiety (BT); and (iii) a second targeting moiety (CY), wherein (i), (ii), and (iii) are fixed, combined, or connected by means of any L; BT is a fibroblast activation protein (FAP)-specific binding ligand structure; CY is an integrin subunit αvβ3 or αvβ6-specific binding ligand structure; L is selected from one or a combination of L1, L2, L3, L4, L5, L6, and L7; L1, L2, L3, L4, L5, L6, and L7 are each independently a key, a monovalent joint, a divalent joint, or a trivalent joint. Also provided are a preparation method for the compound and use thereof.

The invention discloses a bone-strengthening lactoprotein extract as well as a preparation method and application thereof, and belongs to the technical field of deep processing of cow milk. The bone-strengthening milk protein extract contains bone-strengthening active peptide FYPELFR. The preparation method specifically comprises the following steps: (1) pasteurization; (2) separating casein; (3) pepsin hydrolysis; (4) trypsin hydrolysis; (5) purifying and desalting; and (6) concentrating and drying. The bone-strengthening active peptide and the bone-strengthening lactoprotein extract containing the bone-strengthening active peptide can be combined with integrin alpha v beta 1 through hydrophobic interaction and hydrogen bonds, proliferation and differentiation of osteoblasts are promoted by activating a specific signal channel, proliferation of the osteoblasts is promoted, and the bone-strengthening active peptide and the bone-strengthening lactoprotein extract can be used for development of bone-strengthening functional food or drugs and have important significance on deep processing of cow milk.

The invention discloses a preparation method and application of a novel hybrid extracellular vesicle. According to the invention, vesicles derived from endothelial cells and neutrophil cells are combined with deferoxamine, and a biological mixed nano vesicle platform (DFO (HEVS)) is developed to solve the problem of diabetes wound healing. According to the dual-targeting system, DFO is accurately delivered to a wound part by utilizing CXCR4 mediated endothelial cell homing and beta2 integrin dependent inflammation tropism, DFO (at) HEVs activates and recovers vascular regeneration through HIF-1alpha / VEGF, ferroptosis is inhibited through Nrf2 / GPX4 signal transduction, macrophages are reprogrammed into a repair promoting M2 phenotype, and oxidative stress-inflammation-ferroptosis circulation is effectively broken.

Compositions and methods comprising integrin β8 antibodies are provided.

An exosome comprising at least one exosome marker protein selected from among CD63, CD81 and CD9, and an integrin α and / or an integrin β in a lipid bilayer is disclosed. This exosome allows drug delivery with high target selectivity.

A bispecific binding molecule having high selectivity for Kv1.3 but different affinity for integrin β7, a pharmaceutical composition thereof, and a use thereof. The bispecific binding molecule is formed by the fusion of a toxin polypeptide that binds to a Kv1.3-type potassium ion channel and heavy chain or light chain variable region CDRs of an antibody that specifically binds to integrin β7. The obtained bispecific binding molecule has higher selectivity for Kv1.3high β7high T cells (relative to Kv1.3low β7high T cells), and can greatly improve the therapeutic efficacy, while preventing possible adverse reactions caused by other cells that positively express integrin β7. The described difference in binding activity toward two targets enables the bispecific binding molecule to have a binding preference for the two targets, thereby having certain advantages in the design of antibody drugs.

The invention discloses a tumor targeting reagent and application thereof in tumor diagnosis. The targeting reagent has strong affinity to tumors, strong specificity and no biotoxicity, is relatively stable in vivo, and can be used as a molecular probe to be applied to molecular imaging and / or treatment of various integrin alpha6 high-expression tumors; the targeting reagent provided by the invention comprises the tumor targeting peptide RWYDeA, and further comprises a radionuclide chelating agent, other connecting structures and a hydroxyl substitution structure, and the structure is beneficial to improving the tumor targeting property of the targeting reagent, prolonging the tumor binding time and achieving a better tumor diagnosis effect; the method can be used for preparing products for diagnosing / treating diseases related to high expression of integrin alpha6.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

The present disclosure relates, in part, to radiopharmaceuticals that target integrin, such αvβ6, their pharmaceutical compositions, and their use in imaging, diagnosing, and treatment of conditions associated with overexpression of integrins as well as to methods of making these compositions, including high purity 61Cu[Cu] radiopharmaceuticals that target integrins.

The invention belongs to the technical field of collagen skin care products, and provides an oil-soluble recombinant collagen bionic nano-liposome delivery system and a preparation method and application thereof.The preparation method comprises the steps that A, a buffer solution with the pH being 3.8-4.2 is added into a lipid film, oscillation and ultrasonic treatment are conducted, and blank liposome is obtained; b, dissolving the integrin alpha6beta4 transmembrane protein by using a buffer solution with the pH value of 7.2-7.4; adding the transmembrane protein solution into blank lipidosome, oscillating and incubating at 37 DEG C, and performing ultrafiltration and centrifugation to obtain lipidosome suspension; c, dropwise adding the recombinant collagen solution into the liposome suspension, stirring at a constant temperature of 40 + / -2 DEG C, and performing ultrasonic treatment to obtain a collagen liposome suspension; and D, homogenizing the collagen liposome suspension at high pressure, and performing ultrafiltration purification to obtain the purified collagen liposome suspension. Through the technical scheme, the problems of low collagen encapsulation efficiency and low transdermal efficiency in the prior art are solved.

The present invention relates to use of a JWA polypeptide in the preparation of a drug for resisting androgenetic alopecia. An amino acid sequence of the polypeptide is shown as I or II: I: FPGSDRF-Z; II: X-FPGSDRF-Z, wherein an amino acid S is subjected to phosphorylation modification, and X and Z are an amino acid or an amino acid sequence, respectively. The described JWA polypeptide can directly target integrin molecules onto hair follicle cells and enter the cells to play a role in regulating and controlling hair follicle proliferation, promoting hair growth and the like; the telogen phase of the hair follicles is significantly shortened, and the anagen phase of the hair follicles is prolonged; the hair shaft and follicle volume is increased; and the expression level of the target cell integrin molecule αvβ1 can be improved, and the hair follicle stem cell signal channel MEK / ERK / E2F1 / SP1 / Wnt10a / 10b / β-catenin can be accurately activated.

The invention discloses a peptoid compound and a complex thereof, and a pharmaceutical composition comprising the peptoid compound, the peptoid compound can target integrin proteins such as alpha v beta 5 or alpha 5 beta 1 or alpha v beta 3, is enriched in tumor cells with high expression of integrin, and can be used for preparing medicines for treating tumors. The peptoid compound and the complex and the pharmaceutical composition thereof can be used for diagnosis and / or treatment of tumors.

Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.

Provided are an immune checkpoint inhibitor containing as an active ingredient a substance that inhibits the interaction of integrin and immunosuppressive receptor (referred to hereinafter as LILR) B3 and a therapeutic agent for immune checkpoint-related disease containing as an active ingredient a substance that inhibits the interaction of integrin and LILRB3.

The invention relates to the technical field of biology, in particular to an engineered vesicle carrying mRNA targeting and application of the engineered vesicle to improvement of fibroblast functionality. The iRGD polypeptide carried by the engineered vesicle is used as a targeting polypeptide of fibroblasts, specifically targets human dermal fibroblasts and can be combined with rich integrin alpha v and NRP-1 on cell membranes of the fibroblasts, meanwhile, the iRGD polypeptide and exosome surface mask protein emp2b construct a fusion protein, MS2 capsid protein is fused in exosome, and the human dermal fibroblasts can be specifically targeted to the human dermal fibroblasts. According to the present invention, with the combination of the mRNA containing the MS2 stem loop, the more target mRNA can be obtained, such that the more target mRNA can enter the senescent fibroblast in the targeting manner so as to improve the activity of the fibroblast and delay the senescence of the human skin;

Provided is a method and a medicament for treating endometriosis in a subject in need thereof, comprising administering to the subject an effective amount of an Integrin Subunit Beta 2 antagonist.

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

Provided herein are compounds that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

The invention relates to a construction method and application of a retinal artery occlusion disease risk assessment model. Specifically, according to the retinal artery occlusion disease risk assessment model, a retinal artery occlusion disease risk assessment result of a subject is obtained based on the RAO protein marker level of a biological sample of the subject; wherein the RAO protein marker is a combination of integrin subunit alpha M, sex hormone binding globulin, S100 calcium binding protein A7, immune globulin heavy chain delta and synaptic-like protein 1. The prediction accuracy of the retinal artery occlusion disease risk prediction model can reach 88%, the area (AUC) under the working characteristic curve of a subject reaches 0.944, and extremely high distinguishing efficiency and clinical application value are shown.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

Provided herein is a method for inspecting irAE enteritis, comprising a detection step for detecting an antibody that immunologically reacts with a fragment or all of integrin [alpha] v [beta] 6 in a sample as an indicator of ulcerative colitis-like irAE enteritis.

The application relates to small molecule compounds of the general Formula (I) and pharmaceutical compositions comprising them for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulcerative colitis and Crohn's disease.

Disclosed in the present invention are an immunoglobulin κ-type light chain (Vκ4-1-IgLC) polypeptide having a unique Vκ4-1 and the use thereof. The amino acid sequence of the Vκ4-1-IgLC polypeptide is as shown in SEQ ID NO. 1, and the polypeptide can be used as a target or a marker for preparing a drug for diagnosing and / or treating tumors or inflammatory diseases, and can also be used for preparing an Integrin-FAK signal pathway inhibitor. An antibody prepared by using the polypeptide as an antigen can effectively inhibit the development of tumors, and provides a new thought for clinical diagnosis and treatment of tumors.

The application belongs to the field of biomedical application, and more particularly relates to a cell fluorescence probe anchoring cell integrin, and a preparation method and application thereof. The cell fluorescence probe comprises a polypeptide complex, a fluorescent molecule and a cyclodextrin unit, the polypeptide complex comprises a cysteine-containing peptide, a peptide containing a bonding group and a targeting peptide which are connected in any order, the cyclodextrin unit contains a carbon-carbon double bond functional group, and is combined with the cysteine-containing peptide through a click reaction to form the polypeptide complex, the polypeptide complex is covalently connected to the fluorescent molecule through the bonding group, and the fluorescent molecule is an aggregation-induced emission compound. The double bond functional group of the modified cyclodextrin is bonded to the sulfhydryl group of the terminal cysteine of the polypeptide through a click reaction, and the sulfhydryl group of the terminal cysteine of the polypeptide is bonded to the double bond functional group of the modified cyclodextrin through a click reaction, so that the cyclodextrin is improved to protect the fluorescent molecule and prolong the fluorescent time effectiveness of the fluorescent imaging reagent.

Methods treating an aberrant activation of αvβ integrin are provided. The methods include administering a therapeutically effective amount of inducible co-stimulator ligand (ICOSL) polypeptide to a subject in need thereof. Methods of identifying subjects having a kidney injury are also provided.